Cargando…
Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer
OBJECTIVE: Patients with triple-negative breast cancer (TNBC) frequently develop resistance to chemotherapy. Studies have shown that microRNAs (miRNAs) are often aberrantly expressed in TNBC and are associated with drug resistance. However, a prognostic strategy that correlates miRNAs with chemother...
Autores principales: | C, Ahammad Sameer, Shah, Manan, Nandy, Dipayan, Gupta, Reeshu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505887/ https://www.ncbi.nlm.nih.gov/pubmed/37378935 http://dx.doi.org/10.31557/APJCP.2023.24.6.2043 |
Ejemplares similares
-
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010) -
CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy
por: Lemesle, Marine, et al.
Publicado: (2022) -
Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016) -
AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020) -
Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
por: Si, Yingnan, et al.
Publicado: (2021)